Navigation Links
Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Date:2/9/2011

ore study entry.  Patients enrolled in this study need not have a genetic mutation responsive to Amigal as a monotherapy.  Each patient will receive ERT alone and then ERT after administration of a single oral dose of Amigal.  There will be two cohorts of nine patients treated with one of two Amigal dose levels.

The primary outcome measure will be a comparison of the ERT activity in plasma and safety and tolerance with and without coadministration of Amigal.  The effect of co-administration of ERT on the pharmacokinetics and safety of Amigal will also be evaluated.  A secondary outcome measure includes distribution of the ERT to skin.  Other outcome measures include evaluating the effect of co-administration of Amigal and ERT on GL-3 levels in skin and GL-3 excretion in urine.  Amicus expects results from this study to be available in the second half of 2011.

Approximately five clinical sites will participate in this trial in the United States and in Europe.

About Amigal

On October 29, 2010, Amicus announced a definitive agreement with GSK to develop and commercialize Amigal (migalastat HCl), currently in Phase 3, for the treatment of Fabry disease as a monotherapy. Under the terms of the agreement, GSK received an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl. As part of the agreement, GSK and Amicus also intend to investigate Amigal as a potential treatment for Fabry disease when co-administered with ERT.  

The Phase 3 study (Study 011) of migalastat HCl is ongoing and patients are being enrolled at 36 investigational sites worldwide.  A majority of the planned 60 patients have been enrolled in the study. The Company expects to complete enrollment in the first half of 2011 and to report top line results from this study in the second half of 2011.

Amicus and GSK intend to commence an additional Phase 3 study (Study 012) in t
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)...  Conkwest, Inc., the Natural Killer Cell Company ... (NK) cell-line platform, Neukoplast® (NK-92™) as an immuno-oncology ... NantWorks founder, physician scientist and biotechnology entrepreneur, has ... $48 million of the Company,s Class A Common ... be named Co-Chairman of the Conkwest Board of ...
(Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... IRIDEX Corporation (Nasdaq: IRIX ) today announced the receipt of an ... No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent ... product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser ... The Adjustable ...
... Denmark , July 29 AdvanDx today ... a fast, 90 minutes protocol for its Yeast Traffic ... PNA FISH turn-around time from the original 2.5 hours ... 90 minutes to 30 minutes.  Clinical validation studies performed ...
Cached Medicine Technology:IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery 2IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery 3AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 3AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH® 4
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... Webcast to Follow, ROCKVILLE, Md., Oct. 30 ... biopharmaceutical company focused on the development,and commercialization of ... announced it will release results for the,quarter ended ... before the,market opens. A full text copy of ...
... COLORBLENDS will,donate a portion of the proceeds ... collection to the Christopher and Dana Reeve Foundation,(CDRF), ... cures for spinal cord injury and improving the ... Forward collection, available from COLORBLENDS online and,through its ...
... with families in ... the MetroHealth NICU, CLEVELAND, Oct. 30 ... hopes to spend time with,their newborn baby. The NICU is designed to ... the mission of the,March of Dimes to find the answers that will ...
... City Council to Vote on Measure Thursday, WASHINGTON, ... fillings in your mouth are actually composed of 50% ... your dentist office,and currently is not. Councilwoman Blondell Reynolds ... Bill No. 040904 which ensures that patients are,given the ...
... , TUESDAY, Oct. 30 (HealthDay News) -- Quality of life ... locally advanced non-small cell lung cancer, U.S. researchers report. , ... tumor size along with other empirical data to predict how ... of life is a critical factor in determining survival," lead ...
... American College of Physicians (ACP) will publish "Peripheral Arterial ... Key Diseases Series, the book is designed to provide ... and treatment of peripheral arterial disease (PAD), a condition ... a buildup of plaque in the arteries that supply ...
Cached Medicine News:Health News:Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007 2Health News:COLORBLENDS to Donate Portion of Sales of Spring Forward Daffodil Blend to the Christopher and Dana Reeve Foundation 2Health News:Browns Wives Host Special Day at MetroHealth Medical Center to Support the Neonatal Intensive Care Unit 2Health News:Browns Wives Host Special Day at MetroHealth Medical Center to Support the Neonatal Intensive Care Unit 3Health News:A Patients Right to Know: 'Silver Fillings' are 50% Mercury 2Health News:Quality of Life Predicts Lung Cancer Survival 2
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Inquire...
Medicine Products: